Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia

By File Thomas M.   Milkovich Gary   Tennenberg Alan M.   Xiang Jim X.   Khashab Mohammed M.   Zadeikis Neringa  

Current Medical Research and Opinion, Vol. 20, Iss. 9, 2004-09 ,pp. : 1473-1481

Informa Healthcare

Access to resources Recommend Favorite

A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis

By Klausner Howard A.   Brown Patricia   Peterson Janet   Kaul Simrati   Khashab Mohammed   Fisher Alan C.   Kahn James B.  

Current Medical Research and Opinion, Vol. 23, Iss. 11, 2007-11 ,pp. : 2637-2645

Informa Healthcare

Access to resources Recommend Favorite

Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study*

By Frei C. R.   Jaso T. C.   Mortensen E. M.   Restrepo M. I.   Raut M. K.   Oramasionwu C. U.   Ruiz A. D.   Makos B. R.   Ruiz J. L.   Attridge R. T.   Mody S. H.   Fisher A.   Schein J. R.  

Current Medical Research and Opinion, Vol. 25, Iss. 4, 2009-04 ,pp. : 859-868

Informa Healthcare

Access to resources Recommend Favorite

Clinical efficacy of levofloxacin 500 mg once daily for 7 days for patients with non-gonococcal urethritis

By Takahashi Satoshi   Ichihara Kohji   Hashimoto Jiro   Kurimura Yuichiro   Iwasawa Akihiko   Hayashi Kenji   Sunaoshi Kenichi   Takeda Koichi   Suzuki Nobukazu   Satoh Takashi   Tsukamoto Taiji  

Journal of Infection and Chemotherapy, Vol. 17, Iss. 3, 2011-06 ,pp. : 392-396

Springer Publishing Company

Access to resources Recommend Favorite

Adverse event monitoring in oncology clinical trials

By Russell Jeffery S   Colevas A Dimitrios  

Clinical Investigation, Vol. 3, Iss. 12, 2013-12 ,pp. : 1157-1165

Future Science

Access to resources Recommend Favorite